SOUTH SAN FRANCISCO, Calif.,
May 8, 2018 /PRNewswire/
-- Titan Pharmaceuticals, Inc. (NASDAQ:TTNP), a company
developing proprietary therapeutics for the treatment of select
chronic diseases utilizing its ProNeura™ long-term, continuous drug
delivery technology, today announced that its first quarter 2018
financial results will be released after market close on
Tuesday, May 15, 2018.
Due to a scheduling conflict, Titan will host a live conference
call to discuss the financial results and provide a general
business review the following day, May 16,
2018, at 4:15 p.m. ET /
1:15 p.m. PT. The call will be hosted
by Sunil Bhonsle, president and CEO;
Kate Beebe DeVarney, Ph.D.,
executive vice president and chief scientific officer; Brian Crowley, vice president of finance; and
Marc Rubin, M.D., executive
chairman.
The live webcast and a replay of the call may be accessed by
visiting http://www.titanpharm.com/news/events. The call can also
be accessed by dialing 1-855-940-9476 (or 1-412-317-5223 from
outside the U.S.) five minutes prior to the start time, and asking
to be joined into the Titan Pharmaceuticals, Inc. call.
About Titan Pharmaceuticals
Titan Pharmaceuticals, Inc. (NASDAQ:TTNP), based in South San Francisco, CA, is developing
proprietary therapeutics primarily for the treatment of select
chronic diseases. The company's lead product is
Probuphine®, a novel and long-acting formulation of
buprenorphine for the long-term maintenance treatment of opioid
dependence. Probuphine employs Titan's proprietary drug delivery
system ProNeura™, which is capable of delivering
sustained, consistent levels of medication for three months or
longer. Approved by the U.S. Food and Drug Administration in
May 2016, Probuphine is the first and
only commercialized treatment of opioid dependence to provide
continuous, around-the-clock blood levels of buprenorphine for six
months following a single procedure. The ProNeura technology has
the potential to be used in developing products for treating other
chronic conditions such as Parkinson's disease and hypothyroidism,
where maintaining consistent, around-the-clock blood levels of
medication may benefit the patient and improve medical outcomes.
For more information about Titan, please visit
www.titanpharm.com.
Forward-Looking Statements
This press release may contain "forward-looking statements"
within the meaning of Section 27A of the Securities Act of 1933 and
Section 21E of the Securities Exchange Act of 1934. Such statements
include, but are not limited to, any statements relating to our
product development programs and any other statements that are not
historical facts. Such statements involve risks and uncertainties
that could negatively affect our business, operating results,
financial condition and stock price. Factors that could cause
actual results to differ materially from management's current
expectations include those risks and uncertainties relating to the
commercialization of Probuphine, the regulatory approval process,
the development, testing, production and marketing of our drug
candidates, patent and intellectual property matters and strategic
agreements and relationships. We expressly disclaim any
obligation or undertaking to release publicly any updates or
revisions to any forward-looking statements contained herein to
reflect any change in our expectations or any changes in events,
conditions or circumstances on which any such statement is based,
except as required by law.
CONTACTS:
Sunil Bhonsle
President & CEO
(650) 244-4990
Stephen Kilmer
Investor Relations
(650) 989-2215
skilmer@titanpharm.com
View original content with
multimedia:http://www.prnewswire.com/news-releases/titan-pharmaceuticals-to-report-first-quarter-2018-financial-results-on-may-15-2018-300644912.html
SOURCE Titan Pharmaceuticals, Inc.